Patent ID: 8329408
Filing Date: 2012-12-11
Classification: A61P,C12Q,G01N

Abstract:
1. A method for monitoring the response of a patient being treated for breast cancer by administering sorafenib in determining the course of therapeutic treatment, said method for monitoring comprising the steps of: (a) determining the level of expression of one or more biomarker(s) in a first biological sample taken from the patient prior to treatment with sorafenib; (b) determining the level of expression of the one or more biomarker(s) in at least a second biological sample taken from the patient subsequent to the initial treatment with sorafenib; and (c) comparing the level of expression of the one or more biomarker(s) in the second biological sample with the level of expression of the one or more biomarker(s) in the first biological sample; wherein a change in the level of expression of the one or more biomarker(s) in the second biological sample compared to the level of expression of the one or more biomarker(s) in the first biological sample as compared to statistically valid changes in the baseline level of expression of the biomarker(s) in other patients showing an effective response to sorafenib indicates the effectiveness or lack thereof of the treatment with sorafenib, wherein said one or more biomarker(s) is HER-2, EGFR, and soluble forms thereof, and wherein